INMB
Inmune Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.54
−1.91%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.58
From 52W high−38.65%
Volume156565.00
Market cap$42.74M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.58
From 52W high
−38.65%
Volume
156565.00
Market cap
$42.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
28.1
MomentumView details →
1D Return
−1.91%
YTD Return
−1.92%
SummaryUpdated Jun 1, 2026
INmune Bio, Inc. (NASDAQ:INMB) is a clinical-stage immunotherapy company founded in 2015 and headquartered in Boca Raton, Florida. The company went public in February 2019 and focuses on developing innovative treatments that reprogram the patient's innate immune system to combat disease. INmune Bio operates three distinct therapeutic platforms targeting neuroinflammation in Alzheimer's disease, oncology applications through novel NK cell therapy, and rare diseases affecting skin integrity.
Similar companies
Latest newsMore news →
Inmune Bio, Inc. and Quantum Computing Inc. announced a collaboration to apply quantum optimization and AI to INmune Bio’s Alzheimer’s drug research and explore new applications for XPro.6d agoINmune Bio Inc. appointed R. Duane Clark II and James Sapirstein as directors, effective September 8, 2026, each receiving an option to purchase 100,000 shares.35d ago